Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. (2021)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjh.16733
PubMed Identifier: 32449159
Publication URI: http://europepmc.org/abstract/MED/32449159
Type: Journal Article/Review
Volume: 192
Parent Publication: British journal of haematology
Issue: 1
ISSN: 0007-1048